Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Xeris Biopharma reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.07, and improved from a loss of $0.14 per share a year ago, representing an earnings surprise of 14.29% [1] - The company achieved revenues of $60.12 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.76% and up from $40.64 million year-over-year [2] - Xeris Biopharma's stock has increased by approximately 32.2% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $63.36 million, and for the current fiscal year, it is -$0.11 on revenues of $264.52 million [7] - The estimate revisions trend for Xeris Biopharma is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Xeris Biopharma belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Another company in the same industry, Zevra Therapeutics, is expected to report a quarterly loss of $0.21 per share, with revenues anticipated to be $15.8 million, reflecting a significant year-over-year increase of 360.6% [9][10]